20 Spinal Muscular Atrophy Clinical Trials in Sacramento, CA (2026)

Q: How do I join a clinical trial in Sacramento?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Sacramento

NCT06769126Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tes...

Sacramento, CAPHASE2900 participantsSWOG Cancer Research Network

View Study Details

NCT07513376Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with...

Sacramento, CAPHASE3876 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05384626Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activ...

Sacramento, CAPHASE1840 participantsNuvalent Inc.

View Study Details

NCT05208762Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect i...

Sacramento, CAPHASE1714 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT04174157Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a sel...

Sacramento, CA700 participantsNovartis Pharmaceuticals

View Study Details

NCT06917079Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumo...

Sacramento, CAPHASE1665 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06040541Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors....

Sacramento, CAPHASE1604 participantsRevolution Medicines, Inc.

View Study Details

NCT06128551Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors....

Sacramento, CAPHASE1534 participantsRevolution Medicines, Inc.

View Study Details

NCT07218146Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer....

Sacramento, CAPHASE3480 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT07185997Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) ...

Sacramento, CAPHASE3480 participantsArriVent BioPharma, Inc.

View Study Details

NCT06101277Recruiting

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary o...

Sacramento, CANA300 participantsUniversity of California, Davis

View Study Details

NCT07393555Recruiting

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients wi...

Sacramento, CAPHASE2117 participantsSWOG Cancer Research Network

View Study Details

NCT06103682Recruiting

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Sacramento, CANA100 participantsUniversity of California, Davis

View Study Details

NCT04302025Recruiting

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors tha...

Sacramento, CAPHASE299 participantsGenentech, Inc.

View Study Details

NCT06046495Recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSC...

Sacramento, CAPHASE181 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT05467748Recruiting

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung...

Sacramento, CAPHASE166 participantsVA Office of Research and Development

View Study Details

NCT07250477Recruiting

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with pr...

Sacramento, CAPHASE256 participantsUniversity of California, Davis

View Study Details

NCT06287775Recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients w...

Sacramento, CAPHASE145 participantsNational Cancer Institute (NCI)

View Study Details

NCT06228482Recruiting

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC)....

Sacramento, CAPHASE140 participantsUniversity of California, Davis

View Study Details

NCT07012031Recruiting

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

This phase I/II trial tests the safety, side effects and best dose of sotorasib with trastuzumab deruxtecan and how well the combination works in treating patients with KRAS G12C mutated non-small cel...

Sacramento, CAPHASE137 participantsNational Cancer Institute (NCI)

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Sacramento

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 20 spinal muscular atrophy clinical trials recruiting participants in Sacramento, CA. These studies are seeking a combined 7,734 participants. Research is being sponsored by SWOG Cancer Research Network, Merck Sharp & Dohme LLC, Nuvalent Inc. and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Sacramento — FAQ

Are there spinal muscular atrophy clinical trials in Sacramento?

Yes, there are 20 spinal muscular atrophy clinical trials currently recruiting in Sacramento, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Sacramento?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.

Are clinical trials in Sacramento free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 20 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov